Innovative medicine Ocrevus (Ocrelizumab) enters Georgia’s pharmaceutical market. It is the first and only therapy approved for both primary progressive and relapsing forms of multiple sclerosis. . The innovative treatment of the disease was discussed at a scientific conference held under the auspices of company Roche Georgia.
The conference was attended by a special guest from Switzerland, Professor Ludwig Kappos, Head Physician of the Department of Neurology and Outpatient Clinic at the University Hospital of Basel. The conference was also attended by representatives of medical field and media.
Ocrevus is a new term for the treatment of multiple sclerosis. It is the first and only therapy approved for both primary progressive and relapsing forms of Multiple Sclerosis (MS).
According to organizers of the conference, the new drug significantly reduces the disease activity and disability progression. According to specialists, the disease is mainly observed in young women 20-40 years old, but Georgian citizens are not able to complete a full range of medical treatment as drugs are not affordable and neither is reimbursed by insurance companies.
According to the incomplete statistics, 1100 patients have diagnosis of multiple sclerosis in Georgia. “The problem is that it occurs mainly young people from 20 to 40 people and mainly women. The ladies all over the world are more often infected with this disease. In the past 20 years, the world has declared a fractured fight against this disease. The present medicine is an innovative treatment of this disease, but in our country these patients can not get full treatment as these drugs are very expensive, it costs at least 1000 lari per month. patient turns numb hands and legs, restricted movement, worsened eyesight. It repeats time by time. These medicines prevent the progression of disability. It’s funded all over the world by state or insurance companies. It’s very important to bring this tendency in Georgia too, as patients are very young,’’- explains professor of Clinical Neurology Department of Tbilisi State University, Marina Janelidze.
‘’Ocrevus is a new option of treatment. Patients with primary progressive multiple sclerosis, who have never had an approved treatment, will have the opportunity to be treated with this therapy.. Ocrevus is an impressive novelty in both forms of multiple sclerosis treatments. This therapy may radically change the lives of patients and their families, “was said at the conference.
The goal of the Scientific Conference is to launch Ocrevus in the recommendations of multiple sclerosis treatments that will make modern medicine achievements available for Georgian patients.
“We believe that this treatment can radically change the lives of MS patients and their families. What is the most important for us is that we can continue to deliver Innovative medicines for people with serious diseases and that the people who need our medicines are able to get them, We look forward to working with all stakeholders in the healthcare community to ensure that people with MS in Georgia have access to scientific breakthrough’’ says Nino Ganugrava, Roche Georgia Medical Doctor.